BioMarin Buying Alesta Therapeutics For Up To $490M
By Al Barbarino · August 18, 2026, 5:41 PM EDT
Jones Day-advised BioMarin Pharmaceutical Inc. said Tuesday it has agreed to acquire Alesta Therapeutics for $275 million upfront and up to another $215 million tied to the development and regulatory progress...
To view the full article, register now.